Newswise — ATLANTA — According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, there is a profound ongoing need for additional medications to control the signs and symptoms of juvenile idiopathic arthritis (JIA), despite the availability of several approved biologic disease-modifying antirheumatic drugs (biologics) (Abstract #1813). 

There are several biologics used for JIA treatment in the United States including etanercept, adalimumab, abatacept, tocilizumab and canakinumab. Nevertheless, many children with JIA continue to have active arthritis despite the available medications and are treated with other medications off-label. Medications that have been proven to be safe and effective in adults with chronic inflammatory arthritis are not being universally studied in children with JIA. This study’s goal was to document the continuing medical need for additional, newly approved medications to treat children with JIA.

“The approved treatment options for JIA have expanded tremendously, but there are still significant proportions of children who do not respond to available therapies or who are receiving medications that have not been approved for JIA. We must demand that newly developed medications are studied for safety and effectiveness in children,” says Timothy Beukelman, MD, MSCE, associate professor, Division of Pediatric Rheumatology, at the University of Alabama at Birmingham, and the study’s co-author.

For the study, the researchers reviewed electronic medical record data for 1,599 JIA patients treated at Cincinnati Children’s Hospital Medical Center (CCHMC) since 2008 for medication use and disease activity over time. In addition, they assessed 7,379 JIA patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry for medication use and disease activity at their most recent registry visit. The researchers defined ongoing medication need as active JIA despite sequential use of two or more biologics. They defined active JIA as either physician global assessment of JIA activity (on a scale of zero to 10 with zero as inactive disease) of three or higher, or three or more active joints, or a patient global assessment score (on a scale of zero to 10 with zero meaning very well) of three or higher. They only assessed medication failure for patients with complete data.

Use of biologics was common in both data sources (53 percent in CCHMC; 65 percent in CARRA registry), and ongoing medication need was assessed in 487 CCHMC patients and 1,159 CARRA patients. Approximately 52 percent of CCHMC patients and 45 percent of CARRA patients had ongoing active JIA despite treatment with two or more biologics. Among all patients who received any biologic treatments, there was frequent use of medications that are not approved for JIA (37 percent CCHMC patients and 24 percent CARRA patients).

“There is clearly a need to increase the number and types of therapies available for the treatment of children with JIA. Only if FDA demands studies from the pharmaceutical companies as part of their drug development program, will pediatric rheumatologists have valid information about the proper dosing, efficacy and preliminary safety of new medications. Further, FDA approval greatly increases access of JIA patients to new medications,” says Hermine I. Brunner, MD, MSc, MBA, chief of rheumatology and director Lupus Center at Cincinnati Children’s Hospital Medical Center, and scientific director of the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the study’s lead- author.




About the ACR/ARP Annual Meeting

The ACR/ARP Annual Meeting is the premier meeting in rheumatology. With more than 450 sessions and thousands of abstracts, it offers a superior combination of basic science, clinical science, tech-med courses, career enhancement education and interactive discussions on improving patient care. For more information about the meeting, visit, or join the conversation on Twitter by following the official #ACR19 hashtag. 

About the American College of Rheumatology

The American College of Rheumatology (ACR) is an international medical society representing over 8,500 rheumatologists and rheumatology health professionals with a mission to empower rheumatology professionals to excel in their specialty. In doing so, the ACR offers education, research, advocacy and practice management support to help its members continue their innovative work and provide quality patient care. Rheumatologists are experts in the diagnosis, management and treatment of more than 100 different types of arthritis and rheumatic diseases.


New Medications Are Needed for Children with Juvenile Idiopathic Arthritis

Background/Purpose: Existing legislation in the United States (US) promotes the study of new medications in children.  Biologic disease-modifying-drugs (bDMARDs) and small molecules proven effective and safe in adults with rheumatoid arthritis and other forms of inflammatory arthritis require testing in children with juvenile idiopathic arthritis (JIA) to establish proper dosing, effectiveness, and safety. Several bDMARDs have been approved for the treatment of JIA in the US, but not all children with JIA have a complete clinical response to the available medications and are treated with medications off-label (i.e., anakinra, golimumab, infliximab, rituximab, secukinumab, tofacitinib, ustekinumab). The purpose of this research was to document the continuing medical need for new approved medications for the treatment of JIA.

Methods: The electronic medical record of JIA patients (n= 1599) treated at Cincinnati Children’s Hospital Medical Center (CCHMC) since 2008 were reviewed for medication use and disease activity over time. JIA patients enrolled in the Childhood Arthritis & Rheumatology Research Alliance (CARRA) Registry (n=7,379) were assessed for medication use and disease activity at the most recent Registry visit. Medication need was defined as active JIA despite sequential use of ≥2 bDMARDs. Active JIA was defined as either a) physician-global assessment of JIA activity (MD-global; 0-10; 0 = inactive) >3 OR b) number of active joints (AJC) >3 OR c) patient-global assessment of well-being (Pt-global; 0-10; 0=very well) >3. Medication failure was only assessed for patients with complete data (a-c).

Results: At CCHMC, polyarticular-course JIA (40%), systemic JIA (9%) and juvenile psoriatic arthritis/enthesitis-related arthritis (JPSA/ERA; 17%) were common, and only 16% had persistent-oligoarticular JIA. Overall, use of bDMARDs (n=829; 53%) was common. Systemic JIA (85%) and jPSA/ERA patients (79%) were most commonly treated with bDMARDs.  At least 5% (25/1599) of patients had failed >5 bDMARDs. Of 829 biologic users in the CCHMC cohort, 304 (37%) children were exposed to non-approved bDMARDs.  Among 278 CCHMC patients with jPSA /ERA 27 (9.7%) had failed >2 bDMARDs. In the CARRA Registry, 46% of JIA patients had polyarticular disease course, 8% systemic JIA, and 18% jPSA/ERA; 4766 (65%) children had received a bDMARD with 1122 (24%) of these children receiving bDMARDs off label.  Among 1351 jPSA/ERA patients in the CARRA Registry, about 10% failed >2 bDMARDs with active disease at their most recent visit. Table 1 summarizes medication failures in both cohorts.

Conclusions: Data from a population-based cohort and a large national registry demonstrate a profound medical need for additional therapies to control JIA signs and symptoms, despite the availability of several approved biologic DMARDs. Given FDA approval ensures bDMARD access, the testing of new medications in JIA as they become available to treat adults is critical to further improve JIA outcomes.

Register for reporter access to contact details

2019 ACR/ARP Annual Meeting